Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
Open Access
- 9 September 2020
- Vol. 12 (9), 1006
- https://doi.org/10.3390/v12091006
Abstract
Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online relational database. Results: As of August 2020, the Coronavirus Antiviral Research Database (CoV-RDB; covdb.stanford.edu) contained over 2800 cell culture, entry assay, and biochemical experiments, 259 animal model studies, and 73 clinical studies from over 400 published papers. SARS-CoV-2, SARS-CoV, and MERS-CoV account for 85% of the data. Approximately 75% of experiments involved compounds with known or likely mechanisms of action, including monoclonal antibodies and receptor binding inhibitors (21%), viral protease inhibitors (17%), miscellaneous host-acting inhibitors (10%), polymerase inhibitors (9%), interferons (7%), fusion inhibitors (5%), and host protease inhibitors (5%). Of 975 compounds with known or likely mechanism, 135 (14%) are licensed in the U.S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds. Conclusion: CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (NIH/NIAID R24AI136618)
This publication has 117 references indexed in Scilit:
- Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirusProceedings of the National Academy of Sciences of the United States of America, 2013
- Differential Cell Line Susceptibility to the Emerging Novel Human Betacoronavirus 2c EMC/2012: Implications for Disease Pathogenesis and Clinical ManifestationThe Journal of Infectious Diseases, 2013
- Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family FiloviridaeArchiv für die gesamte Virusforschung, 2012
- SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmissionCurrent Opinion in Virology, 2011
- Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory SyndromePLoS Medicine, 2006
- SARS–associated Coronavirus Replication in Cell LinesEmerging Infectious Diseases, 2006
- Pneumonitis and Multi-Organ System Disease in Common Marmosets (Callithrix jacchus) Infected with the Severe Acute Respiratory Syndrome-Associated CoronavirusThe American Journal of Pathology, 2005
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005
- Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeysVirology, 2004
- Regulation of the Interferon System: Evidence that Vero Cells have a Genetic Defect in Interferon ProductionJournal of General Virology, 1979